KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Depreciation & Amortization (CF) (2020 - 2025)

Aurinia Pharmaceuticals' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.04% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $19.4 million, changed 0.02%, while the annual FY2025 figure was $19.4 million, 0.02% changed from the prior year.
  • Depreciation & Amortization (CF) reached $4.9 million in Q4 2025 per AUPH's latest filing, roughly flat from $4.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.3 million in Q3 2023 to a low of -$6.1 million in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $2.0 million, with a median of $916000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 5633.33% in 2021, then tumbled 223.16% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at -$1.4 million in 2021, then plummeted by 38.04% to -$1.9 million in 2022, then crashed by 223.16% to -$6.1 million in 2023, then soared by 179.73% to $4.9 million in 2024, then increased by 0.04% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Depreciation & Amortization (CF) are $4.9 million (Q4 2025), $4.9 million (Q3 2025), and $4.9 million (Q2 2025).